Sentence examples for no valuation of from inspiring English sources

There was no valuation of the company as part of the I.P.O., though some sites say that Yelp could be looking at between $1 billion and $2 billion.

But there is usually no cash changing hands, no valuation of the assets transferred, and ultimately no change of control since the state is simply rejigging its holdings.

By tracing the line upward in each branch to the top of the tree, one observes that no valuation of a in the left branch will result in all the sentences in that branch receiving the value true (because of the presence of a and ∼a).

It adds that no valuation of the property assets was included in the offer documents because these contained public information only; and that there was no third-party involvement in the sale of the food business to Auchan because IFIL's board members felt confident about the terms of the deal.

No valuation of assets would be undertaken and that each town was responsible for discharging any outstanding loans as of 31 December 1907.

As there are no valuations of the general population available for Austria, we compared our sample of medical students with valuations of the general population of Germany [ 12].

"As a private partnership, there is no regular valuation of the business, as any such valuations are only carried out if there is a particular purpose, such as death or sale or purchase of interests.

Rather than Wild West cowboys and girls making big bad speculative bets with what amounted to funny money (since there was no required valuation of such wagers), the marketplace started serving a legitimate purpose: allowing businesses and investors to hedge legitimate credit risks related to trading positions and other assets.

No official valuation of the estate has surfaced since a Bremer Trust attorney estimated during a hearing in June that it could be worth $100 million to $300 million.

There was no parliamentary debate, no proper feasibility study and no third-party valuation of the hydrofoils.

However, it appears that there is no general or unique scope for these pathways and no established monetary valuation of the cost pathways for any disease.